Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival

Abstract Background The effect of first‐line chemotherapy on overall survival (OS) may be significantly influenced by subsequent therapy for patients with extensive disease small cell lung cancer (ED‐SCLC). Therefore, we evaluated the relationship between progression‐free survival (PFS), post‐progre...

全面介绍

书目详细资料

Principais autores:	Ken Masubuchi, Hisao Imai, Satoshi Wasamoto, Takeshi Tsuda, Hiroyuki Minemura, Yoshiaki Nagai, Yutaka Yamada, Takayuki Kishikawa, Yukihiro Umeda, Ayako Shiono, Hiroki Takechi, Jun Shiihara, Kyoichi Kaira, Kenya Kanazawa, Hirokazu Taniguchi, Takayuki Kaburagi, Hiroshi Kagamu, Koichi Minato
格式:	Artigo
语言:	Inglês
出版:	Wiley 2022-10-01
丛编:	Thoracic Cancer
主题:	atezolizumab carboplatin etoposide overall survival post‐progression survival
在线阅读:	https://doi.org/10.1111/1759-7714.14621
标签:	添加标签 没有标签, 成为第一个标记此记录!